BioSpace News Archive

DORADO, PUERTO RICO / ACCESSWIRE / January 5, 2021 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced the appointment of Kirk Michel as Chairman of the Board of Directors, effective January 4, 2021. Mr. Michel has served as

CASPR Group announced that its CASPR 1000 In-Duct disinfection technology kills 98 percent of SARS-CoV-2 viruses on surfaces within six hours and 99.99 percent within 24 hours, according to a recent study conducted by the University of Wisconsin-Madison.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that InMed will be participating in the following virtual investor and partnering conferences in January 2021.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted a stock option to purchase 115,000 shares of its common stock to a new employee, pursuant to the Cidara Therapeutics, Inc.

Lattice Biologics Ltd. at the request of the Investment Industry Regulatory Organization of Canada, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and trading volume of its common shares.

NAMSA ® Acquires Syntactx to Enhance End-to-End CRO Development Solutions, Expanding Medical Device Clinical Research Capabilities and Expertise TOLEDO, Ohio & NEW YORK--( BUSINESS WIRE )-- NAMSA , the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of New York-based CRO, Syntactx . This acquisition follows independent healthcare investment fir

GW Pharmaceuticals plc, the world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that Justin Gover, GW’s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am ET.

KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology and related medical systems, announces the latest advancement in endoscopic imaging.

eLab assay is geared for on-site testing applications such as nursing homes, schools, travel venues, and businesses

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in January.